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Development of Fluorescent Probes 
that Target Serotonin 5-HT2B 
Receptors
Jhonny Azuaje1,2,3, Paula López1,2,3, Alba Iglesias3,4, Rocío A. de la Fuente3,4, José M. Pérez-
Rubio1,2, Diego García1, Tomasz Maciej Stępniewski5, Xerardo García-Mera2,3, José M. Brea3,4, 
Jana Selent5,6, Dolores Pérez1,2, Marián Castro3,4, María I. Loza3,4 & Eddy Sotelo1,2,3
Some 5-HT2B fluorescent probes were obtained by tagging 1-(2,5-dimethoxy-4-iodophenyl)-propan-
2-amine (DOI) with a subset of fluorescent amines. Some of the resulting fluorescent ligands showed 
excellent affinity and selectivity profiles at the 5-HT2B receptors (e.g. 12b), while retain the agonistic 
functional behaviour of the model ligand (DOI). The study highlighted the most salient features of the 
structure-activity relationship in this series and these were substantiated by a molecular modelling 
study based on a receptor-driven docking model constructed on the basis of the crystal structure of 
the human 5-HT2B receptor. One of the fluorescent ligands developed in this work, compound 12i, 
specifically labelled CHO-K1 cells expressing 5-HT2B receptors and not parental CHO-K1 cells in a 
concentration-dependent manner. 12i enables imaging and quantification of specific 5-HT2B receptor 
labelling in live cells by automated fluorescence microscopy as well as quantification by measurements 
of fluorescence intensity using a fluorescence plate reader.
The biogenic amine serotonin, 5-hydroxytryptamine (5-HT), is one of the most versatile chemical messengers in 
the central and peripheral nervous systems1. In addition to its well-known role as a neurotransmitter2, regulating 
virtually all brain functions and neurophysiological processes, 5-HT controls critical functions3 within cardio-
vascular, pulmonary, gastrointestinal and genitourinary systems. Consequently, serotonin has been implicated 
in the etiology of numerous disease states4 (e.g., depression, anxiety, schizophrenia, obsessive-compulsive and 
panic disorders, migraine, hypertension, pulmonary hypertension, eating disorders, vomiting and irritable bowel 
syndrome). The large diversity of functions of serotonin is paralleled by the pharmacological complexity of ser-
otonin receptors5. Of the 14 mammalian 5-HT receptor subtypes, all but one (5-HT3) belong to the super-family 
of G protein-coupled-receptors (GPCRs)5, 6, which mediate most of the serotonin-based signalling network by 
receiving and modulating complex information6, 7.
The 5-HT2 receptor family comprises three closely related receptor subtypes8, 9, namely 5-HT2A, 5-HT2B, and 
5-HT2C, that are the molecular targets of prominent drugs acting in different therapeutic areas1–4, 9–11 (e.g., schizo-
phrenia, depression, hypertension, anxiety). 5-HT2 receptor subtypes mediate many of the central and peripheral 
physiological functions of serotonin1–4 and they couple preferentially to Gq/11 to increase the hydrolysis of inositol 
phosphates (IPs) and elevate cytosolic Ca2+. This similar functional behaviour is supported by a high structural 
homology8, 9. 5-HT2A, 5-HT2B, and 5-HT2C receptors share approximately 46–50% amino acid sequence identity, 
with the homology being higher than 70% within the transmembrane domains (which contain the 5-HT2 bind-
ing pocket)8, 9. Accordingly, the development of highly selective ligands that target a particular 5-HT2 receptor 
subtype constitutes a considerable challenge. The recent resolution of the crystal structure of the 5-HT2B receptor7 
provides new opportunities for the rational discovery of novel small-molecule modulators of 5-HT receptors.
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The 5-HT2B subtype remains one of the most attractive and enigmatic receptors amongst the 5-HT recep-
tor superfamily12, 13, with key functional, signalling, and regulatory aspects remaining ambiguous. The involve-
ment of this receptor in the development of migraine14, the modulation of the 5-HT transport system15, and the 
rewarding and reinforcing effects of the widely abused drug ecstasy (3,4-methylenedioxy-N-methylamphetamine, 
MDMA) has been validated16. 5-HT2B receptor also participate in other relevant processes, particularly in the 
cardiovascular system where it regulates cardiac development and cardiomyocyte proliferation and survival17, 18. 
5-HT2B activation has been associated with diverse pathologies19, 20 (e.g., cardiac hypertrophy and pulmonary 
hypertension). It has been shown that 5-HT2B activation, along with the inhibition of serotonin transporters, 
plays a significant role in the pathogenesis of serotonin-induced valvular abnormalities20–22. In line with these 
observations, it has been demonstrated that norfenfluramine (a metabolite of the antiobesity drug fenfluramine 
that exhibits potent 5-HT2B agonist activity) and other 5-HT2B agonists used in the treatment of migraine induce 
valvular heart disease23–25. Similarly, it was recently verified that the use of the antiparkinsonian dopaminergic 
agonists cabergolide and pergolide (both of which also exhibit high 5-HT2B agonism) is associated with mitral, 
aortic, and tricuspid valvular heart disease26, 27. Accordingly, drugs that are able to activate 5-HT2B receptors and/
or increase circulating serotonin levels are considered to be potential valvulophatic inducers and, as a conse-
quence, 5-HT2B agonism is considered a dangerous off-target effect22, 27–29, thus hampering the promising thera-
peutic potential of 5-HT2B receptor28. However, our understanding of the role of 5-HT2B receptor and an in-depth 
knowledge of the processes triggered by ligand−5-HT2B receptor interactions in living cells are still limited due 
to the lack of ad hoc molecular probes.
The introduction of fluorescence-based techniques has progressed the study of GPCR pharmacology to the 
single cell level30. Fluorescent molecular probes have proven to be valuable tools that offer a wealth of relevant 
evidence31, 32, particularly the mapping or identification of ligand binding sites, ligand binding mechanisms, the 
physical nature of the binding pocket, the movement and internalization of receptors in living cells, and the local-
ization and visualization of labelled receptors. Furthermore, fluorescent probes represent a safer, less expensive 
and faster alternative to radioligands. The extensive application of these techniques to GPCR research demands 
the development of fluorescently labelled GPCR ligands that have appropriate photochemical and pharmacolog-
ical properties. A number of fluorescent probes have been described for 5-HT1A33, 5-HT334 and 5-HT635 receptors 
but, to the best of our knowledge, reports concerning fluorescently-tagged 5-HT2 ligands have not been published 
to date. As part of a project aimed at developing molecular probes for the study of the 5-HT2 receptor family, we 
report here the development and optimization of fluorescent tools that selectively target 5-HT2B receptors. The 
new ligands combine good fluorescence properties with satisfactory affinity and selectivity; accordingly, these 
molecular probes can contribute to a better understanding of the physiological and pathological implications of 
5-HT2B receptors.
Results and Discussion
1-(2,5-Dimethoxy-4-iodophenyl)-propan-2-amine (DOI)36 was selected as the reference ligand to develop the 
fluorescent probes designed within this study. DOI is a partial agonist derived from the amphetamine chemotype 
and it is one of the most useful and better pharmacologically characterized molecular tools for the study of the 
5-HT2-receptor family37, 38. In addition, the [125-I]-R-DOI radioligand is recognized as a reference standard for 
high throughput screening campaigns at 5-HT2 receptors39, 40. Recent findings have shown that DOI produces 
a super-potent (≈15 pM) blockade of the pro-inflammatory effects of tumor necrosis factor alpha (TNF-α) in 
primary aortic smooth muscle cells and animal models41, 42. These findings, which provided new evidence about 
the role of 5-HT2A receptors in inflammation, increase the demand for DOI-based fluorescent probes. For this 
study, it was decided to employ racemic DOI as reference, accordingly all molecular probes were synthesized and 
tested as racemates.
DOI is a well-recognized specific 5-HT2 ligand that, notwithstanding, exhibits weak selectivity within the 
5-HT2 receptor family (5-HT2A, 5-HT2B, 5-HT2C)36–38. Previous reports have evidenced the introduction of func-
tionalized alkyl chains on the methoxy group at position 2 of the phenyl ring in DOI produces an increased 
5-HT2B selectivity43. This structure-activity relationship trend encouraged us to explore the use of DOI-based 
derivatives for the development of fluorescent ligands for the 5-HT2B receptor. A set of acid-functionalized DOI 
derivatives (7a–d) bearing variable spacers on the oxygen atom at position 2 was synthesized (Fig. 1) according 
to previously described procedures44–48. With the aim of carrying out a preliminary evaluation of the biologi-
cal repercussions of the different spacers, precursors 7a–d were transformed into the corresponding fluorescent 
derivatives 10a–d by reacting with a model dansyl amine (8a) and subsequent cleavage of the Boc groups (Fig. 1).
The fluorescent probes 10a–d contain the 1-(2,5-dimethoxy-4-iodophenyl)-propan-2-amine scaffold and the 
dansyl chromophore linked through variable spacers that differ in both length and composition (Fig. 2). The 
results of the pharmacological evaluation of the model fluorescently-tagged amides 10a–d at the 5-HT2 receptor 
family (5-HT2A, 5-HT2B, 5-HT2C)49, 50 are presented in Fig. 2. All compounds were evaluated in binding experi-
ments (see experimental part) and the results were compared with the biological activity determined for the ref-
erence ligand (DOI). Additionally, the functional activities (IPs accumulation)51 of the compounds at the 5-HT2B 
receptor were also determined (Fig. 2).
In agreement with previous findings43, it was verified that the introduction of alkyl chains on the oxygen atom 
at position 2 of the phenyl ring of the amphetamine scaffold produces derivatives that exhibit incipient 5-HT2B 
subtype selectivity (10a–d, Fig. 2). The drop observed in the 5-HT2A affinity is particularly noteworthy as this is in 
the micromolar range for all of the dansyl probes tested. Another remarkable trend identified on considering the 
biological data (Fig. 2) obtained for DOI derivatives bearing dansyl as a fluorescent tag (10a–d) is the importance 
of the spacer group linking the pharmacophore and the fluorophore. It was observed that elongation of the spacer 
has a negative effect on both the affinity and activity at the 5-HT2B receptor (Fig. 2), with the fluorescent probe 
bearing the propyl group (10a) displaying the most attractive affinity and selectivity profiles.
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Figure 1. Synthesis of the target fluorescent DOI analogues44–48. Reagents and conditions: (a) K2CO3, R–X, 
MeCN, 80 °C, 8 h. (b) I2, THF, rt, 24 h. (c) Me-NO2, AcOH, 100 °C, 6 h. (d) Fe, AcOH, 100 °C, 12 h. (e) NH4OAc, 
NaCNBH4, THF, 2 h. (f) (Boc)2O, THF, 0 °C, 3 h. (g) DCC, DCM, rt, 12 h (70–93%). (h) HCl/Dioxane, DCM, 
0 °C, 2 h (50–78%).
Figure 2. Structural and pharmacological data at 5-HT2 receptors of model dansyl probes bearing different 
linkers (10a–d).
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In an effort to shed light on the molecular determinants for the binding of the novel fluorescent probes, we 
used the recent crystallized structure of the 5-HT2B receptor (PDB ID: 4IB4)7 to create three-dimensional models 
of this receptor in complex with two fluorescent derivatives with different linker lengths: compound 10a (3 car-
bon linker) and 10b (5 carbon linker). The resulting complexes were embedded in a physiological environment 
consisting of a hydrated lipid bilayer and then subjected to extended molecular dynamics simulations with a 
total simulation time of 1.6 µs. A common binding pose was obtained for the DOI fragment for both simulated 
systems and this fragment is inserted deep into to the 5-HT2B receptor (Fig. 3, inset top panel). The protonated 
nitrogen of DOI establishes a strong electrostatic interaction with D3.32 whereas the aromatic ring is sandwiched 
in a hydrophobic environment formed by a valine in position 3.33 and two phenylalanines in positions 6.51 and 
6.52. This tight binding results in a stable pose along the simulation, as reflected by low RMSD values of 0.761 Å 
(compound 10a) and 0.703 Å (compound 10b) with respect to the average structure (Fig. 3, lower panel). In con-
trast, the fluorescent tag that is linked to position 2 of the aromatic ring and reaches towards the extracellular side 
of the 5-HT2B receptor shows much higher dynamic variability around the average structure, with an RMSD of 
2.144 Å for ligand 10a and 3.732 Å for compound 10b. The general higher fluctuation for both fluorescent probes 
is due to interaction with areas of higher flexibility in the extracellular loop region of the receptor. This situation 
Figure 3. Three-dimensional complexes of the fluorescent probes 10a (left) and 10b (right) bound to the 
5-HT2B receptor obtained from extended molecular dynamics simulation with a total time of 1.6 μs (2 
times × 800 ns). The upper panel highlights ligand-receptor interactions of a representative structure. The lower 
panel includes information about the dynamic properties and stability of the ligand binding by depicting frames 
each 50 ns along a total simulation time of 800 ns. The RMSD values are calculated for DOI or the fluorescent 
tag with respect to the average structure at 800 ns.
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is inevitable as the fluorescent tag needs to reach sufficiently far out of the receptor in order to avoid undesired 
quenching interactions with the receptor, which would give rise to a non-functional fluorescence probe.
Despite this higher fluctuation, it was found that during the course of the simulation compound 10a (3 carbon 
linker) formed frequent polar interactions with the backbone of ECL 2 and Q7.32 via the SO2 group (Fig. 3, top 
left panel), which result in a stabilization of the fluorescent tag (RMSD 2.144 Å, bottom left panel). Such polar 
stabilization is reduced for compound 10b because the longer linker architecture (5 carbon linker) is not optimal 
for allowing this polar interaction. Such reduced stabilization could be a plausible explanation for the reduced 
binding affinity observed for compound 10b (5 carbon linker, Ki: 167.19 nM) compared to compound 10a (3 car-
bon linker, Ki: 111.70 nM). The model developed here predicts that compounds with a longer linker have reduced 
stabilizing interactions in the extracellular loop regions and therefore exhibit lower binding affinity. This predic-
tion is consistent with the other experimental data. For example, compound 10c (9 carbon linker, Ki 806.04 nM) 
has a markedly lower binding affinity compared to compound 10a (3 carbon linker, Ki: 111.70 nM) and 10b (5 
carbon linker, Ki 167.19 nM).
The propyl spacer group present in the most pharmacologically appealing fluorescent probe identified (10a) 
was fixed for subsequent fluorophore exploration. Accordingly, the carboxylic acid 7a was combined with a set 
of 9 propylamine-functionalized fluorescent tags (Fig. 4) by employing classical coupling experimental con-
ditions (Fig. 4)44–48. The selection of fluorescent amines (8) embraced not only classical fluorescent tags (e.g., 
8a,b or 8i) but also several new fluorescent scaffolds (e.g., 8c–h). The employed tags (8) incorporate fluores-
cent groups with relatively small to large molecular volumes, thus providing a collection of probes with diverse 
structural and photophysical properties. Some of the non-conventional fluorophores were chosen on the basis 
Figure 4. Synthesis of the target fluorescent DOI analogues 12a–i and structures of the fluorescent amine 
precursors (8a–i). Reagents and conditions: (a) DCC, DCM, rt, 12 h (70–93%). (b) HCl/Dioxane, DCM, 0 °C, 
2 h (50–78%).
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of their complementary absorption/emission fluorescence spectra, since they could be employed as donor and 
acceptor pairs for the implementation of fluorescence resonance energy transfer (FRET) studies in the near 
future. Amines 8d–8g were prepared from the corresponding dimethyl phenanthrene-9,10-dicarboxylates 
(or pentaphene-6,7-dicarboxylate, for 8g), these aromatic o-diesters were synthesized by palladium-catalyzed 
[2 + 2 + 2] cycloaddition of arynes52, 53 with dimethyl acetylenedicarboxylate (see supporting information). The 
experimental details for the syntheses of compounds 12 are outlined in Fig. 4. Briefly, the carboxylic acid 7a was 
reacted with different fluorescent amines (8a–i) employing DCC as a coupling reagent to give the amides 11. 
Finally, the protecting group (BOC) was removed by treatment with TFA to afford the fluorescent DOI-based 
probes 12a–i. Details on the synthesis, structural and photo-physical characterization of the obtained fluorescent 
probes are described in the experimental part and in Fig. 4.
The absorption and emission spectra of the fluorescent 5-HT2 ligands (10 and 12) were determined on 10 μM 
solutions. The most relevant fluorescent properties are collected in Fig. 5. All of the synthesized derivatives emit-
ted fluorescence in the visible region of the spectrum, with selected fluorescent tags (Fig. 4) providing distinctive 
properties and excitation wavelengths. The excitation wavelengths varied from 305 to 555 nm, whereas those for 
emission varied from 398 to 580 nm. Most of the compounds showed satisfactory Stokes shift values (Fig. 5).
As for the first series described above, the pharmacological characterization of the resulting fluorescent lig-
ands (12) was performed at two levels. Firstly, the in vitro affinity was assessed by radioligand binding assays at 
the three 5-HT2 receptor subtypes. Subsequently, the functional activity at the 5-HT2B receptors was evaluated 
(IPs accumulation). The data are collected in Fig. 6 and some of the representative curves obtained are shown in 
Fig. 7. It can be observed that all compounds stimulated IPs accumulation in a concentration-dependent manner, 
with EC50 values in the nanomolar range. These data confirm that the novel ligands retain the agonist behaviour 
exhibited by the model ligand (DOI).
Examination of the pharmacological data contained in Fig. 6 reveals the identification of some highly attrac-
tive fluorescent ligands (e.g., 12b–f). Most of the fluorescent probes retain the incipient 5-HT2B selectivity profile 
observed for the former member of the series (10a). Taking advantage of the existing X-ray structure, we per-
formed docking followed of molecular probes from the 12 series (12a to 12i) into the 5-HT2B receptor (PDB ID: 
4IB4). All probes have overlapping docking poses (Figs 3 and 8) forming common interactions of the DOI frag-
ment with residues D3.32, V3.33, F6.51 and F6.52 in the orthosteric binding pocket, as previously observed in our 
molecular dynamics simulations. In addition, we find that two residues, Q7.32 and the backbone of K211 at the 
extracellular loop clamp the polar part of the fluorophore tag (highlighted as red dashed lines in Fig. 8). The linker 
length determines the position of the fluorophore and its polar region with respect to the polar extracellular loop 
region. As discussed above, it is likely that longer linkers limit such favourable polar interaction. The obtained 
binding modes (Fig. 8) provide a potential explanation for affinity differences of studied compounds. According 
to our models, it appears that solvent exposure is an important factor for binding affinity towards the 5-HT2B 
receptor. Comparing dyes 12a to 12h (Fig. 8) suggests that increased and unfavourable exposure of complex and 
hydrophobic probes that reach out into the solvent seems to be responsible for a drop of 5-HT2B affinity.
Figure 5. Photophysical properties of fluorescent DOI probes 12a–i.
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The obtained data support the benefits of introducing the acid-functionalized linker on the oxygen atom 
at position 2 of the phenyl ring of the model ligand (DOI), but also highlight the need for the optimized alkyl 
spacer (X = CH2−CH2−CH2). It should be noted that most of the fluorescent probes exhibited weak affinity (typ-
ically micromolar range) at the 5-HT2A and 5-HT2C receptors, while the functional experiments confirmed their 
agonistic behaviour (Fig. 7). Moreover, a progressive drop in 5-HT2B affinity was observed when the molecular 
complexity of the dye increased (e.g. cpds 12g–i). Of the probes obtained, the 7-nitrobenz-2-oxa-1,3-diazole 
(NBD) labelled DOI ligand (12b) warrants particular attention as it is slightly less potent (Ki = 90.99 nM) than 
the reference ligand (DOI, Ki = 48.19 nM) while exhibit an excellent selectivity (≥20-fold) for the 5-HT2B receptor 
subtype. Although the NBD ligand (12b) has the most attractive pharmacological profile, the rhodamine deriva-
tive 12i showed the most promising properties of the series from the photophysical point of view.
Having finished the preliminary photophysical and pharmacological characterization of the fluorescent 
derivatives 12a–i, their potential to specifically label 5-HT2B receptors in live cells was evaluated. Chinese 
hamster ovary K1 (CHO-K1) cells and CHO-K1 cells stably expressing the human serotonin 5-HT2B receptor 
Figure 6. Structures and pharmacological data at 5-HT2 receptors for the DOI-based fluorescent probes 12a–i.
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(CHO-K1-5-HT2B), growing in 96-well plates, were incubated with at least three different concentrations of each 
compound for varying times and, after compound removal and washing of the cells, plates were subjected to 
fluorescence microscopy using a high content imaging instrument and the appropriate excitation and emission 
filter set for each compound.
Unfortunately, substantial specific labelling of 5-HT2B receptors was not observed for compounds 12a–h 
under any of the conditions evaluated. For these compounds, the cellular fluorescence intensities were similar in 
CHO-K1-5-HT2B and in parental untransfected control CHO-K1 cells (data not shown). This non-specific label-
ling of cells independently of 5-HT2B expression might arise due to non-specific membrane binding or membrane 
penetration of the fluorescent ligands, as observed previously for other fluorescent probes for GPCRs54.
While exhibiting a moderate 5-HT2B affinity/selectivity profiles compound 12i displayed a 
concentration-dependent specific labelling of CHO-K1-5-HT2B cells and this resulted in brighter fluorescence 
images obtained from these cells in comparison with those from control CHO-K1 cells (Fig. 9). The best results 
were obtained for a 3 μM concentration of compound 12i, which yielded the maximum window of specific label-
ling of the cells for the concentrations assayed (Fig. 9B). Under these conditions, the fluorescence intensity of 
the images collected from CHO-K1-5-HT2B cell wells was clearly superior to that observed for control CHO-K1 
cell wells (***p < 0.001, two-way ANOVA and Bonferroni posttests), as quantified both by automated image 
analysis and by direct measurement of fluorescence emission on a fluorescence plate reader (Fig. 9C,D). In the 
absence of compound, no substantial fluorescence signal was detected in the cells (Fig. 9A), which indicates a 
lack of signal specificity due to cell autofluorescence. These results support the specific binding of 12i to 5-HT2B 
receptors. Image acquisition at higher magnification (40x) and analysis retrieved similar quantitative results 
(Supplementary Figure S1). Furthermore, confocal microscopy imaging of CHO-K1-5-HT2B cells labelled with 
compound 12i in the same conditions also allowed visualization of the probe fluorescence, mainly located in 
intracellular compartments after 10 min incubation at 37 °C (Supplementary Figure S2).
The specificity and sensitivity of the 12i probe towards 5-HT2B receptors over other 5-HT2 receptor sub-
types was evaluated by performing similar labelling experiments in CHO cells stably expressing 5-HT2A recep-
tors (CHO-FA4-5-HT2A). In this case, no statistically significant specific labelling was detected when compound 
12i was employed at the concentration of 3 μM (Supplementary Figure S3), and it was required to increase the 
12i concentration to 20 μM in order to detect certain specific labelling of 5-HT2A receptors over background. 
However, even in these conditions (20 μM concentration of 12i) the signal window over background achieved for 
5-HT2A labelling was considerably smaller than that detected in the case of 5-HT2B labelling at a concentration of 
12i more than 6 times lower (3 μM) (Fig. 9 and Supplementary Figure S3). These results were in good agreement 
with the affinity values of compound 12i obtained from our radioligand binding assays. Hence, compound 12i 
allows direct visualization of 5-HT2B receptors stably expressed in a cell line by live fluorescence microscopy 
imaging and constitutes a promising molecular probe for future studies.
Conclusions
A set of fluorescent ligands based on the 1-(2,5-dimethoxy-4-iodophenyl)-propan-2-amine (DOI) chemotype 
has been developed. Some of the novel fluorescent probes (e.g. 12b) show excellent affinity and selectivity profiles 
at the 5-HT2B receptors, while retaining the agonistic functional behaviour of DOI. The study highlighted the 
most salient features of the structure-activity relationship in this series and these were supported by a molecular 
modelling study based on a receptor-driven docking model constructed on the basis of the crystal structure of 
the human 5-HT2B receptor. One of the fluorescent ligands reported here enabled the visualization of 5-HT2B 
receptors in live cells. Compound 12i specifically labelled 5-HT2B receptors stably expressed in CHO-K1 cells 
in a concentration-dependent manner in fluorescence microscopy studies. Hence, the probes described here are 
the first examples of 5-HT2B selective fluorescent ligands and their availability should help to boost the GPCR 
biomolecular imaging field, thus enabling direct visualization and monitoring of spatiotemporal changes asso-
ciated with 5-HT2B-related (patho)-physiological states. The ligand might be also useful for other assays where 
well characterized specific fluorescent probes and appropriate signal-to-background window are required, such 
as BRET-based binding assays.
Figure 7. Concentration-response curves obtained for representative ligands and DOI in binding experiments 
(A) and in functional studies (B).
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Methods
Chemistry. Unless otherwise stated, all starting materials, reagents and solvents were purchased and used 
without further purification. The reactions were monitored by thin-layer chromatography (TLC) on 2.5 mm 
Merck silica gel GF 254 strips, and the purified compounds each showed a single spot; unless stated otherwise, 
UV light and/or iodine vapour were used to detect compounds. The purity and identity of all tested compounds 
were established by a combination of HPLC, elemental analysis, mass spectrometry and NMR spectroscopy 
Figure 8. (A) Superimposition of docking poses of compounds 12a–i for the 5-HT2B receptor (PDB ID: 4IB4) 
with following color code: 12a - red, 12b - pink, 12c - green, 12d - yellow, 12e - cyan, 12f - dark blue, 12g - 
purple, 12h - orange and 12i - silver. (B) Individual docking poses for the probes 12a–i bound to the 5-HT2B 
receptor (PDB ID: 4IB4).
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Figure 9. Labelling of 5-HT2B receptors by compound 12i in cells. (A) Living parental untransfected CHO-
K1 cells (CHO-K1) and CHO-K1 cells stably expressing 5-HT2B receptors (CHO-K1-5-HT2B) were incubated 
in the absence or presence of the indicated concentrations of compound 12i and, after compound removal, 
fluorescence images (excitation wavelength 520–550 nm, emission wavelength 560–630 nm, standard filter set 
for 5-TAMRA) were acquired using an automated high content imaging instrument at 20x magnification. (B) 
Sample images from CHO-K1 and CHO-K1-5-HT2B cells labelled with 1 µg/mL Hoechst 33342 (for nuclear 
staining) and compound 12i at a concentration of 3 μM, sampled from those quantified in (C,D). Minimum 
and maximum intensity and gamma correction of the images are shown in the colour scale in the panel. (C,D) 
Quantification of the fluorescence emission of compound 12i in images from CHO-K1 and CHO-K1-5-HT2B 
cells labelled with 1 µg/mL Hoechst 33342 (for nuclear staining) and compound 12i at a concentration of 
3 μM, both by image analysis (C) and by direct fluorescence measurement using a plate reader (D). The graphs 
show mean ± SEM of 4 wells, 5 fields/well (image analysis) and mean ± SEM of the same wells (plate reader). 
***p < 0.001, two-way ANOVA and Bonferroni post tests.
www.nature.com/scientificreports/
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as described below. Purification of isolated products was carried out by column chromatography (Kieselgel 
0.040–0.063 mm, E. Merck) or medium pressure liquid chromatography (MPLC) on a CombiFlash Companion 
(Teledyne ISCO) with RediSep pre-packed normal-phase silica gel (35–60 µm) columns followed by recrystalli-
zation. Melting points were determined on a Gallenkamp melting point apparatus and are uncorrected. The NMR 
spectra were recorded on Bruker AM300 and XM500 spectrometers. Chemical shifts are given as δ values against 
tetramethylsilane as internal standard and J values are given in Hz. Mass spectra were obtained on a Varian MAT-
711 instrument. High-resolution mass spectra were obtained on an Autospec Micromass spectrometer. Analytical 
HPLC was performed on an Agilent 1100 system using an Agilent Zorbax SB-Phenyl, 2.1 mm × 150 mm, 5 µm 
column with gradient elution using the mobile phases (A) H2O containing 0.1% CF3COOH and (B) MeCN and 
a flow rate of 1 mL/min. The purity of all tested compounds was determined to be >95%. The acid functionalized 
DOI precursors were synthesized by following previously described methods44–48. The experimental details of the 
synthesis of amines 8d–g are reported in the supplementary information.
General procedure for the synthesis of fluorescent amides 10 and 12. To a solution of the44–48 car-
boxylic acid (0.2 mmol) in anhydrous dichloromethane (10 mL) at 0 °C was added N,N-dicyclohexylcarbodiimide 
(0.25 mmol). To this mixture was slowly added the corresponding amine 8 (0.2 mmol) in anhydrous dichlo-
romethane (5 mL) and the mixture was stirred at room temperature for 12 h. After completion of the reaction, 
as indicated by TLC, the mixture was diluted with water and extracted with dichloromethane. The organic phase 
was dried (Na2SO4), filtered and concentrated to afford the corresponding amide (11), which was used in the next 
step. To a solution of the amide (11) in dichloromethane (10 mL) at 0 °C was slowly added 4N HCl in dioxane 
(3 mL) and the mixture was stirred for 2 h at room temperature. After completion of the reaction, as indicated 
by TLC, the mixture was neutralized with saturated sodium bicarbonate, diluted with water and extracted with 
dichloromethane. The organic phase was dried over Na2SO4, filtered and concentrated to afford a residue that was 
purified by column chromatography on silica gel to afford the target amide.
(±) 4-(2-(2-aminopropyl)-5-iodo-4-methoxyphenoxy)-N-(3-((5-(dimethyl-amino)naphtha-
lene)-1-sulfonamido)propyl)butanamide (10a, 12a). Green-yellow wax; 75% (102 mg); 1H NMR 
(300 MHz, CDCl3) δ (ppm): 8.50 (dt, J = 8.6, 0.9 Hz, 1H), 8.31 (dt, J = 8.7, 0.9 Hz, 1H), 8.17 (dt, J = 7.3, 1.0 Hz, 
1H), 7.57–7.43 (m, 2H), 7.21–7.08 (m, 2H), 6.79 (t, J = 6.2 Hz, 1H), 6.61 (s, 1H), 3.85–3.71 (m, 6H), 3.29–3.11 (m, 
3H), 2.99–2.74 (m, 9H), 2.60 (t, J = 6.8 Hz, 2H), 2.42–2.19 (m, 2H), 1.98 (t, J = 6.9 Hz, 2H), 1.51 (t, J = 5.6 Hz, 2H), 
1.07 (d, J = 6.3 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ (ppm): 173.2, 152.4, 151.9, 151.6, 135.2, 130.2, 129.8, 129.6, 
129.3, 129.1, 128.3, 123.2, 122.6, 118.9, 115.2, 113.9, 82.8, 67.6, 57.1, 47.3, 45.4, 40.5, 40.1, 35.9, 32.8, 29.6, 25.3, 
23.4. HRMS (ESI) m/z: calcd. for C29H40IN4O5S [M + H]+: 683.1759, found: 683.1760.
(±) 7-(2-(2-aminopropyl)-5-iodo-4-methoxyphenoxy)-N-(3-((5-(dimethylami-no)naph-
thalene)-1-sulfonamido)propyl)heptanamide (10b). Green-yellow wax, 71% (103 mg); 1H NMR 
(300 MHz, CDCl3) δ (ppm): 8.48 (dt, J = 8.5, 1.0 Hz, 1H), 8.33 (dt, J = 8.6, 0.9 Hz, 1H), 8.14 (dt, J = 7.3, 1.2 Hz, 
1H), 7.57–7.41 (m, 2H), 7.22–7.04 (m, 2H), 6.88 (t, J = 5.9 Hz, 1H), 6.69 (s, 1H), 3.92–3.77 (m, 3H), 3.75–3.69 (m, 
3H), 3.28–3.12 (m, 3H), 2.97–2.88 (m, 3H), 2.87–2.78 (m, 6H), 2.24–2.07 (m, 2H), 1.85–1.50 (m, 6H), 1.48–1.20 
(m, 8H). 13C NMR (75 MHz, CDCl3) δ (ppm): 174.7, 156.1, 151.9, 144.6, 134.2, 133.6, 129.8, 129.7, 129.0, 128.9, 
127.5, 124.5, 123.8, 122.3, 119.5, 114.7, 86.5, 68.7, 57.6, 46.2, 44.8, 40.0, 39.5, 38.6, 37.9, 29.7, 29.2, 28.6, 27.1, 26.2, 
22.9. HRMS (ESI) m/z: calcd. for C32H46IN4O5S [M + H]+: 725.2228, found: 725.2216.
(±) 11-(2-(2-aminopropyl)-5-iodo-4-methoxyphenoxy)-N-(3-((5-(dimethyl-amino)naphtha-
lene)-1-sulfonamido)propyl)undecanamide (10c). Green-yellow solid; mp: 171–173 °C, 63% (98 mg); 
1H NMR (300 MHz, CDCl3) δ (ppm): 8.51 (dt, J = 8.5, 1.0 Hz, 1H), 8.32 (dt, J = 8.6, 0.9 Hz, 1H), 8.18 (dt, J = 7.4, 
1.0 Hz, 1H), 7.69–7.38 (m, 2H), 7.23–7.07 (m, 2H), 6.67 (d, J = 8.8 Hz, 1H), 6.03 (t, J = 6.5 Hz, 1H), 3.94–3.82 
(m, 2H), 3.76 (s, 3H), 3.41–3.30 (m, 1H), 3.24 (q, J = 6.3 Hz, 2H), 2.99–2.75 (m, 9H), 2.73–2.60 (m, 1H), 2.09 (t, 
J = 7.5 Hz, 2H), 1.72 (q, J = 7.0 Hz, 2H), 1.63–1.46 (m, 4H), 1.46–1.07 (m, 17H). 13C NMR (75 MHz, CDCl3) δ 
(ppm): 174.0, 152.3, 151.8, 135.3, 130.2, 129.8, 129.6, 129.0, 128.3, 128.1, 123.1, 122.5, 119.0, 115.2, 114.3, 83.1, 
68.7, 57.1, 47.4, 45.4, 45.4, 39.9, 39.5, 36.5, 35.9, 29.6, 29.3, 29.1, 29.0, 29.0, 29.0, 26.0, 25.5, 21.7. HRMS (ESI) m/z: 
calcd. for C36H54IN4O5S [M + H]+: 781.2854, found: 781.2851.
(±) 3-(2-(2-(2-(2-aminopropyl)-5-iodo-4-methoxyphenoxy)ethoxy)ethoxy)-N-(3-((5-(dimeth-
ylamino)naphthalene)-1-sulfonamido)propyl)propanamide (10d). Green-yellow solid; mp: 107–
109 °C, 57% (86 mg); 1H NMR (300 MHz, CDCl3) δ (ppm): 8.53 (dt, J = 8.5, 1.1 Hz, 1H), 8.30 (d, J = 8.7 Hz, 1H), 
8.22 (dd, J = 7.3, 1.3 Hz, 1H), 7.56–7.47 (m, 2H), 7.21–7.11 (m, 2H), 6.83 (t, J = 5.2 Hz, 2H), 6.63 (s, 1H), 3.88 (td, 
J = 6.0, 2.9 Hz, 2H), 3.80 (s, 3H), 3.55 (t, J = 5.0 Hz, 2H), 3.51–3.34 (m, 9H), 3.09 (t, J = 5.0 Hz, 2H), 2.88 (s, 6H), 
2.59 (t, J = 7.0 Hz, 2H), 2.39 (td, J = 7.2, 2.2 Hz, 2H), 2.09 (p, J = 6.7 Hz, 2H), 1.07 (d, J = 6.3 Hz, 3H). 13C NMR 
(75 MHz, CDCl3) δ (ppm): 173.6, 152.5, 151.8, 151.4, 134.8, 130.4, 129.8, 129.6, 129.2, 128.4, 125.9, 123.2, 122.5, 
119.0, 115.3, 114.3, 83.9, 70.0, 69.9, 69.9, 69.3, 68.3, 57.1, 48.2, 45.4, 42.8, 39.2, 36.2, 33.2, 25.3, 18.1. HRMS (CI) 
m/z: calcd. for C32H46IN4O7S [M + H]+: 757.2132, found: 757.2161.
(±) 4-(2-(2-aminopropyl)-5-iodo-4-methoxyphenoxy)-N-(3-((7-nitroben-zo[c][1,2,5]
oxadiazol-4-yl)amino)propyl)butanamide (12b). Orange solid; mp: 158–160 °C; 69% (84 mg); 1H 
NMR (300 MHz, CDCl3) δ (ppm): 8.30 (d, J = 8.8 Hz, 1H), 7.05 (s, 1H), 6.51 (s, 1H), 6.07 (d, J = 8.9 Hz, 1H), 3.79 
(dt, J = 6.3, 4.7 Hz, 2H), 3.64 (s, 3H), 3.40 (dq, J = 8.6, 5.9 Hz, 2H), 3.28–3.16 (m, 3H), 2.90 (dd, J = 13.1, 5.5 Hz, 
1H), 2.57 (dd, J = 13.1, 8.7 Hz, 1H), 2.38–2.26 (m, 2H), 2.01–1.89 (m, 2H), 1.87–1.75 (m, 2H), 1.19–0.94 (m, 
5H). 13C NMR (75 MHz, CDCl3 + MeOD) δ (ppm): 174.5, 152.4, 151.3, 144.2, 137.2, 125.6, 122.3, 114.1, 98.4, 
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83.9, 67.9, 56.8, 41.0, 36.6, 36.5, 36.0, 32.9, 32.9, 29.4, 27.6, 25.3, 17.9. HRMS (CI) m/z: calcd. for C23H30IN6O6 
[M + H]+: 613.1272, found: 613.1270.
(±) 4-(2-(2-aminopropyl)-5-iodo-4-methoxyphenoxy)-N-(3-(1,3-dioxo-1,3-dihydro-
2H-dibenzo[e,g]isoindol-2-yl)propyl)butanamide (12c). Pale-yellow wax; 61% (83 mg); 1H NMR 
(300 MHz, CDCl3) δ (ppm): 9.21–8.94 (m, 2H), 8.72 (ddd, J = 8.7, 1.3, 0.8 Hz, 2H), 7.93–7.62 (m, 4H), 7.21 (q, 
J = 1.5 Hz, 1H), 6.81–6.56 (m, 2H), 4.05–3.84 (m, 3H), 3.77 (d, J = 0.7 Hz, 3H), 3.42–3.18 (m, 3H), 2.77–2.54 
(m, 3H), 2.51–2.41 (m, 2H), 1.93 (dt, J = 13.0, 6.4 Hz, 4H), 1.18 (d, J = 6.3 Hz, 3H). 13C NMR (75 MHz, CDCl3) 
δ (ppm): 174.0, 171.9, 171.8, 155.1, 153.9, 132.2, 131.0, 128.6, 127.4, 127.3, 126.6, 125.4, 123.6, 123.1, 115.2, 
86.3, 68.9, 58.2, 49.3, 40.4, 39.9, 37.4, 32.9, 26.9, 24.9, 22.8. HRMS (ESI) m/z: calcd. for C33H35IN3O5 [M + H]+: 
680.1616, found: 680.1606.
(±) 9-(3-(4-(2-(2-aminopropyl)-5-iodo-4-methoxyphenoxy)butanamido)pro-pyl)-10-methyl 
phenanthrene-9,10-dicarboxylate (12d). Pale-yellow wax; 56% (79 mg); 1H NMR (300 MHz, CDCl3) 
δ (ppm): 8.84 (dt, J = 7.3, 1.8 Hz, 2H), 7.92 (dd, J = 7.5, 1.6 Hz, 1H), 7.87 (dd, J = 7.4, 1.6 Hz, 1H), 7.68 (td, J = 7.5, 
1.6 Hz, 2H), 7.60 (tt, J = 7.5, 1.6 Hz, 2H), 7.15 (s, 1H), 6.64 (s, 1H), 6.58 (s, 1H), 4.22 (td, J = 12.2, 3.2 Hz, 2H), 
4.04–3.86 (m, 5H), 3.81 (s, 3H), 3.60–3.42 (m, 3H), 3.00 (dd, J = 12.4, 6.9 Hz, 1H), 2.54 (dd, J = 12.6, 7.1 Hz, 
1H), 2.35–2.23 (m, 2H), 2.03–1.92 (m, 2H), 1.90–1.80 (m, 2H), 1.70 (s, 2H), 1.05 (d, J = 5.9 Hz, 3H). 13C NMR 
(75 MHz, CDCl3) δ (ppm): 173.7, 168.9, 168.1, 152.4, 151.2, 130.9, 129.8, 129.4, 128.6, 127.7, 127.7, 127.4, 126.7, 
126.5, 125.8, 122.9, 122.4, 122.3, 114.1, 83.8, 67.8, 64.3, 56.9, 52.8, 36.6, 32.9, 29.5, 28.1, 25.2, 22.5, 18.4. HRMS 
(CI) m/z: calcd. for C34H38IN2O7 [M + H]+: 713.1724, found: 713.1739.
(±) 9-(3-(4-(2-(2-aminopropyl)-5-iodo-4-methoxyphenoxy)butanamido)pro-pyl) 10-methyl 
2,3,6,7-tetrafluorophenanthrene-9,10-dicarboxylate (12e). Pale-yellow wax; 52% (82 mg); 1H 
NMR (300 MHz, CDCl3) δ (ppm): 8.54–8.43 (m, 2H), 7.62 (d, J = 8.0 Hz, 1H), 7.52 (d, J = 8.1 Hz, 1H), 7.19 (s, 
1H), 6.64 (s, 1H), 6.27 (s, 1H), 4.16 (td, J = 12.4, 1.9 Hz, 2H), 3.95 (s, 3H), 3.91–3.88 (m, 2H), 3.82 (s, 3H), 3.76 (td, 
J = 12.2, 3.6 Hz, 2H), 3.39–3.32 (m, 1H), 3.01 (dd, J = 12.1, 5.9 Hz, 1H), 2.68 (dd, J = 12.3, 6.1 Hz, 1H), 2.60–2.55 
(m, 2H), 2.15–2.00 (m, 2H), 1.78–1.67 (m, 2H), 1.65 (s, 2H), 1.17 (d, J = 6.0 Hz, 3H). 13C NMR (75 MHz, CDCl3) 
δ (ppm): 174.6, 168.4, 167.8, 157.3, 154.8, 152.4, 151.7, 149.6, 148.7, 129.6, 128.3, 127.3, 127.0, 126.9, 125.6, 124.3, 
123.9, 115.6, 114.4, 113.8, 86.5, 68.3, 63.6, 58.1, 52.3, 47.5, 39.8, 36.9, 32.3, 28.6, 24.3, 22.9. HRMS (ESI) m/z: calcd. 
for C34H34F4IN2O7 [M + H]+: 785.1341, found: 785.1341.
(±) 5-(3-(4-(2-(2-aminopropyl)-5-iodo-4-methoxyphenoxy)butanamido)pro-pyl)-6-methyl-1,2
,3,8,9,10-hexahydrodicyclopenta[b,h]phenanthrene-5,6-dicarbo-xylate (12f). Pale-yellow wax; 
63% (99 mg); 1H NMR (300 MHz, CDCl3) δ (ppm): 8.61–8.44 (m, 2H), 7.96–7.77 (m, 2H), 7.22–7.01 (m, 1H), 
6.71–6.46 (m, 1H), 4.50 (q, J = 6.0 Hz, 2H), 4.00 (s, 3H), 3.90 (t, J = 6.1 Hz, 1H), 3.83–3.58 (m, 5H), 3.45–3.29 (m, 
1H), 3.24–2.99 (m, 11H), 2.97–2.81 (m, 2H), 2.56–2.44 (m, 2H), 2.39–1.79 (m, 8H), 1.14 (d, J = 6.5 Hz, 3H). 13C 
NMR (75 MHz, CDCl3) δ (ppm): 172.9, 169.6, 168.7, 152.4, 151.4, 146.0, 145.8, 144.6, 144.4, 130.2, 127.5, 125.8, 
125.6, 122.6, 122.3, 121.2, 121.1, 117.7, 114.2, 114.0, 83.3, 67.7, 63.6, 57.0, 52.6, 47.5, 38.6, 36.8, 33.2, 32.8, 31.6, 
30.6, 28.3, 25.9, 24.7, 22.6. HRMS (ESI) m/z: calcd. for C40H46IN2O7 [M + H]+: 793.2344, found: 793.2347.
(±) 6-(3-(4-(2-(2-aminopropyl)-5-iodo-4-methoxyphenoxy)butanamido)pro-pyl) 7-methyl 
pentaphene-6,7-dicarboxylate (12g). Pale-yellow solid; mp: 150–152 °C; 64% (104 mg); 1H NMR 
(300 MHz, CDCl3) δ (ppm): 9.15 (d, J = 15.0 Hz, 2H), 8.46 (d, J = 24.9 Hz, 2H), 8.26–7.85 (m, 4H), 7.79–7.32 
(m, 5H), 6.95 (s, 1H), 6.30 (s, 1H), 4.56 (t, J = 6.2 Hz, 2H), 4.06 (s, 3H), 3.80–3.28 (m, 8H), 3.14–2.83 (m, 1H), 
2.61–2.45 (m, 1H), 2.38–2.25 (m, 2H), 2.14–1.81 (m, 4H), 1.30–1.10 (m, 5H). 13C NMR (75 MHz, CDCl3) δ 
(ppm): 173.5, 168.9, 168.1, 152.3, 151.0, 132.7, 132.6, 132.1, 130.6, 130.3, 128.5, 128.4, 128.3, 128.2, 128.1, 127.4, 
126.7, 126.5, 125.5, 124.8, 124.7, 122.4, 122.3, 122.1, 113.8, 83.9, 68.0, 64.7, 56.8, 53.1, 48.2, 36.7, 36.2, 33.4, 28.3, 
25.3, 18.1. HRMS (ESI) m/z: calcd. for C42H42IN2O7 [M + H]+: 813.2031, found: 813.2036.
(±) 4-(2-(2-aminopropyl)-5-iodo-4-methoxyphenoxy)-N-(3-(1,3,8,10-tetraoxo-9-(tridecan-
7-yl)-3,8,9,10-tetrahydroanthra[2,1,9-def:6,5,10-d′e′f′]diisoquinolin-2(1H)-yl)propyl)butana-
mide (12h). Red solid, mp: 169–171 °C; 41% (82 mg); 1H NMR (300 MHz, CDCl3) δ (ppm): 8.44 (d, J = 7.7 Hz, 
2H), 8.18 (d, J = 7.7 Hz, 2H), 8.12–8.05 (m, 4H), 7.48 (brs, 1H), 7.06 (s, 1H), 6.64 (s, 1H), 5.15 (t, J = 6.6 Hz, 1H), 
4.18–4.09 (m, 1H), 4.01 – 3.80 (m, 4H), 3.78–3.71 (m, 1H), 3.65–3.52 (m, 5H), 3.36–3.23 (m, 2H), 3.12–3.04 
(m, 1H), 2.93–2.84 (m, 1H), 2.55 (brs, 2H), 2.29–2.09 (m, 3H), 2.05–1.89 (m, 4H), 1.50–1.06 (m, 19H), 0.85 (t, 
J = 7.2 Hz, 6H). 13C NMR (75 MHz, CDCl3) δ (ppm): 175.5, 162.8, 162.7, 162.6, 162.6, 155.8, 154.1, 139.5, 139.1, 
132.4, 131.8, 131.1, 127.5, 127.5, 126.8, 126.8, 124.9, 124.9, 124.6, 124.5, 124.4, 124.4, 124.4, 124.3, 124.3, 123.8, 
123.8, 123.8, 123.8, 115.8, 87.3, 69.9, 57.1, 54.6, 48.4, 40.5, 38.9, 37.6, 35.7, 34.8, 34.8, 31.7, 31.7, 29.4, 29.4, 26.8, 
26.6, 26.6, 25.7, 23.4 22.9, 22.9, 14.1, 14.1. HRMS (ESI) m/z: calcd. for C54H62IN4O7 [M + H]+: 1005.3657, found: 
1005.3659.
(± )  N-(9-(2-((26-(2-(2-aminopropyl)-5-iodo-4-methoxyphenoxy)-3,7,23-trioxo-
12,15,18-trioxa-4,8,22-triazahexacosyl)carbamoyl)phenyl)-6-(diethylamino)-3H-xanthen-3-y
lidene)-N-ethylethanaminium (12i). Dark red solid, mp: 151–153 °C, 35% (84 mg); 1H NMR (300 MHz, 
CDCl3) δ (ppm): 7.70–7.55 (m, 3H), 7.36–7.11 (m, 6H), 6.79–6.60 (m, 3H), 4.25–4.00 (m, 5H), 3.98–3.86 (m, 3H), 
3.79 (s, 3H), 3.69–3.46 (m, 17H), 3.46–3.26 (m, 6H), 3.16–2.88 (m, 7H), 2.85–2.68 (m, 5H), 2.64–2.37 (m, 2H), 
2.21–1.97 (m, 2H), 1.40–1.10 (m, 15H). 13C NMR (75 MHz, CDCl3) δ (ppm): 173.7, 173.4, 169.4, 169.0, 157.9, 
157.8, 155.6, 152.4, 151.6, 136.1, 132.4, 132.2, 130.2, 129.7, 129.3, 128.1, 126.8, 122.2, 114.5, 113.9, 113.8, 113.7, 
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96.1, 83.6, 69.8, 69.5, 67.9, 63.1, 57.2, 52.9, 51.8, 51.7, 51.3, 50.5, 47.8, 46.0, 44.3, 39.2, 39.1, 38.7, 37.2, 35.3, 34.4, 
30.6, 29.6, 24.9, 24.3, 17.8, 12.6. HRMS (ESI) m/z: calcd. for [C57H78IN8O10]+ [M]+: 1162.5080, found: 1162.5085.
Biological methods. Cell Culture. Chinese hamster ovary K1 (CHO-K1) cells were maintained in 
Dulbecco’s modified Eagle’s medium-F12 (DMEM/F12) (GIBCO, Thermo Fisher Scientific, Spain) supplemented 
with 10% fetal bovine serum (FBS) (Sigma Aldrich, Spain), 2 mM L-glutamine (Sigma Aldrich, Spain) and 100 U/
mL penicillin/0.1 mg/mL streptomycin (Sigma Aldrich, Spain). CHO cells stably expressing 5-HT2A receptors 
(CHO-FA4-5-HT2A) were maintained in DMEM/F12 supplemented with 10% FBS, 2 mM L-glutamine and 100 U/
mL penicillin/0.1 mg/mL streptomycin and 300 μg/mL hygromycin (Invitrogen, Thermo Fisher Scientific, Spain). 
CHO-K1 cells stably expressing the human 5-HT2B receptor (CHO-K1-5-HT2B) were maintained in Advanced 
DMEM/F-12 (GIBCO, Thermo Fisher Scientific, Spain) supplemented with 1% FBS, 4 mM L-glutamine, 10 U/mL 
penicillin/0.01 mg/mL streptomycin and 0.4 mg/mL geneticin (G-418) (GIBCO, Thermo Fisher Scientific, Spain).
Radioligand competition binding assays at human 5-HT2A receptors. Serotonin 5-HT2A receptor competition 
binding experiments were carried out in membranes from CHO-FA4-5-HT2A cells prepared in our group. 
On the day of the assay, membranes were defrosted and resuspended in binding buffer (50 mM Tris-HCl, pH 
7.5). Each reaction well of a 96-well plate contained 80 μg of protein, 1 nM [3H]Ketanserin (50.3 Ci/mmol, 
Perkin-Elmer, Waltham, MA, USA), and different concentrations of the compounds in the range from 0.01 nM to 
10 µM. Non-specific binding was determined in the presence of 1 μM methysergide (Sigma Aldrich, Spain). The 
reaction mixture was incubated at 37 °C for 30 min, after which samples were transferred to multiscreen GF/B 
96-well plates (Millipore, Spain) pretreated with 0.5% polyethylenimine (PEI, Sigma Aldrich, Spain), filtered, and 
washed six times with 250 μL wash buffer (50 mM Tris-HCl, pH 6.6). The filters were dried, 35 μL Universol (MP 
Biomedicals, Spain) per well were added and radioactivity was detected in a microplate beta scintillation counter 
(Microbeta Trilux, Perkin-Elmer, Waltham, MA, USA).
Radioligand competition binding assays at human 5-HT2B receptors. Serotonin 5-HT2B receptor competition 
binding experiments were carried out in membranes from CHO-K1-5-HT2B cells prepared in our group. On 
the day of the assay, membranes were defrosted and resuspended in binding buffer (50 mM Tris-HCl, 4 mM 
CaCl2, 0.1% ascorbic acid, pH 7.4). Each reaction well of a 96-well plate contained 5 μg of protein, 1 nM [3H]
LSD (83.6 Ci/mmol, Perkin-Elmer, Waltham, MA, USA), and different concentrations of the compounds in the 
range from 0.01 nM to 10 µM. Non-specific binding was determined in the presence of 50 μM serotonin (Sigma 
Aldrich, Spain). The reaction mixture was incubated at 37 °C for 30 min, after which samples were transferred to 
multiscreen GF/C 96-well plates (Millipore, Spain) pretreated with 0.5% polyethylenimine (PEI, Sigma Aldrich, 
Spain), filtered, and washed four times with 250 μL wash buffer (50 mM Tris-HCl, pH 7.4). The filters were dried, 
35 μL Universol (MP Biomedicals, Spain) per well were added and radioactivity was measured as described above.
Radioligand competition binding assays at human 5-HT2C receptors. Serotonin 5-HT2C receptor competition 
binding experiments were carried out in membranes from HeLa-5-HT2C cells prepared in our group. On the day 
of assay, membranes were defrosted and resuspended in binding buffer (50 mM Tris-HCl, pH 7.5). Each reaction 
well of a 96-well plate contained 15 μg of protein, 4 nM [3H]Mesulergine (83.5 Ci/mmol, Perkin-Elmer, Waltham, 
MA, USA), and different concentrations of the compounds in the range from 0.01 nM to 10µM. Non-specific 
binding was determined in the presence of 10 μM mianserin (Sigma Aldrich, Spain). The reaction mixture was 
incubated at 27 °C for 1 h, after which samples were transferred to multiscreen GF/C 96-well plates (Millipore, 
Spain) pretreated with 0.5% polyethylenimine (PEI, Sigma Aldrich, Spain), filtered, and washed four times with 
250 μL wash buffer (50 mM Tris-HCl, pH 6.6). The filters were dried, 35 μL Universol (MP Biomedicals, Spain) 
per well were added and radioactivity was measured as described above.
Functional Assays of IPs accumulation at human 5-HT2B receptors. CHO-K1 cells stably expressing human 
5-HT2B receptor (CHO-K1-5-HT2B) cells were seeded into 96-well tissue culture plates at a density of 20000 cells/
well. After 24 h, growth medium was replaced by serum-free medium containing 10 μCi/mL [3H]myo-inositol 
(20.3 Ci/mmol, Perkin-Elmer) for 24 h. After a labelling period of 24 h, cells were washed for 10 min at 37 °C 
with Hanks’ balanced salt solution (HBSS) supplemented with 20 mM HEPES, 20 mM LiCl and 2% fatty acid free 
bovine serum albumin (BSA) (assay buffer) and incubated in assay buffer in the absence (vehicle) or in the pres-
ence of the indicated concentrations of the compounds for 20 min at 37 °C. After the incubation time, assay buffer 
was discarded and 200 μL of 100 mM formic acid was added to the cells for 30 min at 4 °C and 20 μL of the lysate 
were transferred to a flexiplate plate (Perkin-Elmer, Waltham, MA, USA) together with 80 μL of a solution of 
RNA Binding YSi SPA Beads (Perkin-Elmer, Waltham, MA, USA) to measure accumulation of [3H]IPs (IP1,IP2, 
and IP3, collectively referred to as IPs). Radioactivity was quantified in a liquid scintillation counter WALLAC 
Microbeta TriLux 1450-023.
Data analysis of radioligand and functional assays. Concentration-response curves were fitted using Prism ver-
sion 4.0 (GraphPad Software). A nonlinear regression fitting to a four parameter logistic equation and the Cheng–
Prusoff equation were used to calculate EC50 values and Ki, respectively.
Fluorescence microscopy imaging. For cell labelling studies, cells were plated onto 96-well plates (Cell Carrier; 
Perkin-Elmer, Waltham, MA, USA) pre-treated with poly-D-lysine hydrobromide 0.1 mg/mL (Sigma Aldrich, 
Spain) at a density of 10000 cells/well and cultured for 24 h. For cell labelling with compound 12i, cultured media 
was removed and cells were washed with HBSS supplemented with 0.1% BSA and incubated in the same buffer for 
30 min at 37 °C. The buffer was removed and cells were incubated in the absence or presence of the compound at 
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the indicated concentrations in HBSS for 10 min at 37 °C. A 10−2 M stock solution of the compound was prepared 
in DMSO and then diluted to the final assay concentration in HBSS. Hoechst 33342 (1 µg/mL) (Thermo Fisher, 
Spain) was used to stain nuclei where indicated. After the incubation time, the supernatant was removed, cells 
were washed twice with HBSS and plates were subjected to microscopy. Fluorescence images were acquired using 
an Operetta high content imaging instrument (Perkin-Elmer, Waltham, MA, USA) at 20x and 40x magnification, 
at excitation wavelengths of 520–550 nm and emission wavelengths of 560–630 nm (standard 5-TAMRA filter 
set) for compound 12i, and excitation wavelengths of 360–400 nm and emission wavelengths of 410–480 nm for 
Hoechst 33342 (standard Hoechst 33342 filter set).
Quantification of fluorescence intensity. The fluorescence intensity of the cells labelled with compound 12i 
was quantified by image analysis of the acquired images using Harmony v3.5 software (Perkin-Elmer). Object 
identification was performed in the Hoechst channel followed by intensity measurement of the cell area of the 
objects in the 5-TAMRA channel and the results are expressed as the sum of the 5-TAMRA intensity in the cell 
region divided by the sum of cell area in each well. Five fields of view/well and 4 wells/condition were analyzed. 
Fluorescence intensity of the labeled cells was also quantified in the same plates and wells by measuring fluores-
cence emission (excitation wavelength 550 nm, emission wavelength 580 nm) on an Infinite M1000Pro fluores-
cence plate reader (TECAN, Männedorf, Switzerland). Data (mean ± SEM) obtained from both quantification 
methods were represented as bar graphs using Prism version 4.0 (GraphPad Software).
In Silico Methods. Receptor preparation from the X-ray crystal structure. To simulate the interactions of 
5-HT2B with fluorescent probes, we used the recently crystallized structure of the receptor (PDB ID: 4IB4)55. The 
area of the structure, corresponding to the BRIL protein, was cut out. The protonation states were calculated at pH 
7.4 using PROPKA56 software implemented in MOE (http://www.chemcomp.com/software.htm).
Ligand Docking. First, DOI was docked into the 5-HT2B receptor defining a centroid point in the residue 
Asp3.32 and expanding it to 20 Å around this residue using the GOLD software57. One hundred genetic algo-
rithm runs were submitted and further scored employing the ASP scoring function. The ligands were restricted 
to form a salt bridge between their positively charged nitrogen and the carboxylate of Asp3.32. The best poses 
from this docking procedure were used as inputs to explore the conformational space of the ligands with the Low 
Mode Search function of MOE, which is a short MD simulation that uses velocities with little kinetic energy on 
the high-frequency vibrational modes, using the AMBER12:EHT force field, Born solvation, 300 K and default 
settings. The lowest energetic pose was then used as a starting point to link the dansyl probe using MOE. In order 
to explore stability and the conformational space, we carried out extended molecular dynamics (MD) simulations 
for the 5-HT2B receptor in complex with DOI-linked fluorescence probes.
Extended MD simulations. The protein with the ligand docked was then embedded in a 1-palmitoyl-2
-oleoyl-sn-glycero-3-phosphocholine bilayer using Charmm-gui58. Information obtained from the OPM data-
base was employed to ensure proper alignment of the protein in membrane59. The system was solvated with 
TIP3 water. The ionic strength of the system was set to 0.15 M using NaCl ions. Parameters were derived from 
the Charmm36 forcefield. Missing parameters for the ligands were obtained from CGenFF60. Simulations were 
carried out in ACEMD61 and the hydrogen mass-repartitioning scheme employed in ACEMD allowed us to use 
a 4 fs timestep62. The system was minimized for 3000 steps, and then subjected to 2 ns of NPT equilibration at 
a constant pressure of 1.01325 bar to ensure proper lipid packing in the membrane. Afterwards we proceeded 
with NVT simulations at a temperature of 300 K. For each complex (complex 1: 10a-5-HT2B and complex 2: 
10b-5-HT2B) we generated 4 individually built starting structures and simulated them for 200 ns each, yielding a 
total time of 800 ns per complex.
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